Nxera Is Already 83% of the Way to Its Full-Year Profit Target — the Market Hasn't Noticed

Nxera Pharma swung its first-half operating result from a JPY 2.8 billion loss to a JPY 1.9 billion profit and the stock fell 0.5 percent on the news. That's the kind of reaction that tells you the market is still pricing the old story: a Japanese biotech that burns cash on drug discovery, lives on the hope of milestone payments, and will find profitability somewhere in the distant future.

The numbers say something different. In H1 FY2026, Nxera's core operating profit — the metric that strips out milestone and licensing income to show how the underlying business is performing — hit JPY 6.5 billion. The full-year guidance target is JPY 7.8 billion. Nxera has already completed roughly 83 percent of its annual core-profit target in six months, against a year-ago comparison of just JPY 364 million.

The old story

For years, Nxera's revenue has been a mix of growing product sales and lumpy milestone payments from partnerships with big pharma. The FY2025 full year saw revenue climb to JPY 29.6 billion, which looked like progress. But operating losses persisted because R&D and restructuring costs ate through the top-line growth. The earnings trajectory had been declining at an average annual rate of nearly 59 percent. The market priced Nxera as a company that generates interesting science but hasn't figured out how to pay the bills.

The newer evidence

H1 2026 revenue rose 25 percent year-over-year to JPY 18.9 billion. That's not the headline — the headline is how that revenue was composed and what it cost to generate.

Product sales, the recurring part of the business, were JPY 9.9 billion, up 32 percent. PIVLAZ, the migraine medication, contributed JPY 6.3 billion (up 9 percent). QUVIVIQ, the narcolepsy drug that's the real growth engine, jumped 127 percent to JPY 3.6 billion. Management's full-year QUVIVIQ projection sits at JPY 5.0 billion to JPY 6.0 billion, which implies the second half still needs to deliver roughly JPY 1.4 billion to JPY 2.4 billion in additional sales on a drug that has real tailwind in a large, underserved market.

Milestone revenue — the one-off payments from partners — was JPY 8.0 billion, up 60 percent. The sources are identifiable: Neurocrine, AbbVie (third and fourth milestones under a drug discovery collaboration), Centessa, and Eli Lilly (second development milestone on the orexin program). None of these are guarantees for the second half. Milestone income is lumpy by definition. But the company doesn't need another JPY 8 billion in milestones to hit its targets. The core operating profit number tells you why.

The more telling shift is on the cost side. Total costs fell 10 percent, meeting the company's reduction target. SG&A and R&D spending combined are tracking at roughly 49–50 percent of their full-year projections, which means Nxera has burned through about half its planned spending budget while generating the vast majority of its annual core-profit goal. That's the operating leverage that makes the inflection real: the cost base shrank faster than revenue grew, and the product mix is shifting toward the higher-margin asset.

Why the market hasn't moved

The stock closed at ¥865 on August 7, barely registering the turnaround, and remains well below its 52-week high of ¥1,247. Part of the stagnation is structural: Nxera is listed in Tokyo, not New York or London, and the broader biotech crowd is distracted by bigger names and larger deals. But there's also the lingering skepticism about milestone dependence — the memory of FY2025, where revenue growth couldn't overcome operating losses, runs deeper than a single quarter of positive core profit.

That memory is becoming stale. The financial bridge is explicit: H1 core OP of JPY 6.5 billion against a full-year target of JPY 7.8 billion, with costs already well under their annual run rate. If Q2 core profit tracks anywhere close to H1 pace, Nxera doesn't need a miracle in the second half. It needs execution, which is a much smaller ask.

The valuation frame

At ¥865 per share, Nxera's market cap is approximately JPY 80.5 billion. Against the FY2026 revenue guidance of JPY 33.8 billion, the stock trades at roughly 2.4 times projected sales. Against the JPY 7.8 billion core operating profit target, that's about 10.3 times. For a company moving from losses to profitability on the back of a drug that grew 127 percent, those multiples don't reflect the new reality. They reflect the old one.

Management's 2030 targets — JPY 40–50 billion in product revenue and an operating margin above 30% — are still a ways off. But the next 12 months don't require the 2030 vision to play out. They require QUVIVIQ to continue its trajectory and costs to stay disciplined. Both are things Nxera is already doing.

The external validation you can't ignore

Eli Lilly's acquisition of Centessa for $7.8 billion in June wasn't just a headline. Centessa was built around Nxera's StaR stabilized-receptor technology. Lilly completed the acquisition but Nxera retains its rights to future milestone and royalty payments on the orexin receptor agonist programs that Lilly now owns. The $7.8 billion price tag is a third-party stamp on the value of the platform that Nxera's own numbers haven't fully captured yet. Management cited the deal on the earnings call as external validation that the stock trades below intrinsic value.

The risks

Cash is the one area where the picture isn't as clean. As of March 31, cash and equivalents stood at JPY 11.6 billion, down JPY 8.8 billion from the start of the year. The H1 press release didn't publish an updated June 30 balance, so there's a genuine data gap here. The run-rate spending is lower, and operating cash flow should be positive now, but without the Q2 cash figure it's hard to say how much runway the company has beyond the current guidance period. That's worth watching.

The other risk is simpler: QUVIVIQ doesn't keep growing. A 127 percent year-over-year jump is impressive but not automatic. If the second half comes in at the low end of the JPY 5.0 billion to JPY 6.0 billion full-year range, revenue and core profit targets are still achievable, but the rerating case thins. And milestone revenue will almost certainly decline in H2 — that's the nature of milestone income. The thesis doesn't require it, but the market still mentally offsets product gains against the expected drop-off.

What matters next

This is a setup where the market is still pricing a cash-burning biotech while the numbers already point to a company that's learned to generate operating profit. The core operating profit of JPY 6.5 billion in H1 is the one metric that makes the old story stale. At 2.4 times projected sales and 10 times the core profit target, Nxera looks like a company whose financial inflection has already happened but hasn't registered in the price.

The thesis requires QUVIVIQ to deliver on its growth trajectory and costs to stay contained through H2. If Nxera hits or exceeds the JPY 7.8 billion core operating profit target and shows a stabilized cash position in its next report, the rerating becomes harder to ignore. If QUVIVIQ growth stalls below the low end of guidance and cash drops further without explanation, the setup resets and the old story was right all along.

Discipline over ego.